Thaler, R., Spitzer, S., Karlic, H., Klaushofer, K
By the third week, both TZP and TZP+FcLep groups exhibited lower VO 2 and energy expenditure than vehicle and FcLep groups, likely due to reduced body weight (Fig
coli The redox potential of roGFP-iL targeted to the periplasm of E
If hyperkalemia develops, this drug should be discontinued, and a thiazide alone should be substituted
Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al
doi:10.1056/NEJMoa041031 107